Camizestrant: Lower Breast Cancer Risk & Mortality
The SERENA-6 trial delivers promising results, highlighting the efficacy of camizestrant in treating advanced breast cancer. News Directory 3 reports on this important study, which focuses on the significant role of camizestrant in improving progression-free survival for patients with ESR1 mutations. This research also examines the novel cancer treatment approach of serial CDK testing, possibly enabling earlier intervention. Discover the potential for more personalized treatment plans for those battling advanced breast cancer.what breakthroughs are next in this evolving landscape?
SERENA-6 Trial Shows Promise for Advanced Breast Cancer Treatment
Updated June 15, 2025
CHICAGO—A new study suggests a potential shift in treating advanced breast cancer. The SERENA-6 trial, presented at the ASCO Annual Meeting, explored the effectiveness of camizestrant, combined with a CDK 4/6 inhibitor, in patients with hormone receptor-positive, HER2-negative advanced breast cancer who also had an emergent ESR1 mutation. The global, double-blind, phase 3 trial offers new insights into managing this specific type of cancer.
Dr. Erica L. Mayer, director of breast cancer clinical research at Dana-Farber Cancer Institute, highlighted the trial’s findings. Patients who switched to the camizestrant combination experienced a median progression-free survival (PFS) of 16 months, compared to 9 months for those who continued standard treatment with an aromatase inhibitor plus a CDK 4/6 inhibitor. The SERENA-6 trial is a key study in the role of new treatments for advanced breast cancer.
The role of serial CDK testing is also coming to the forefront. According to mayer, the trial introduces the concept of identifying molecular changes before clinical changes occur. This proactive approach may allow for earlier intervention,improving patient outcomes in cancer treatment.
“In general,this was a very exciting presentation,not only showing us the benefit of using camizestrant,a well-tolerated oral SERD in the setting of the growth of molecular progression,but also just introducing us to the concept of serial CDK testing and the idea that one can identify molecular changes before there are clinical changes and that this may be a helpful time to intervene,” Mayer said.
What’s next
Further research will focus on refining the use of camizestrant and exploring the potential of serial CDK testing to personalize treatment strategies for patients with advanced breast cancer.